Generic Daclatasvir ( Daclatasvir )

Order cheap Generic Daclatasvir (Daclatasvir ) without dr prescription in the United States

At our pharmacy, you can purchase Daclatasvir without a prescription, with delivery throughout the USA within 5-14 days. Discreet and anonymous packaging.
Daclatasvir is used for the treatment of chronic hepatitis C virus (HCV) infection, specifically for genotypes 1 and 3, in combination with sofosbuvir (with or without ribavirin). The medication is an NS5A inhibitor that blocks viral replication, helping to achieve sustained virological response (cure).
The usual dosage of Daclatasvir is 60 mg taken once daily, with or without food.
The administration form is tablets (30 mg, 60 mg).
The effect of the medication begins within several days to weeks, with undetectable viral load typically achieved after 4‑8 weeks of treatment.
The duration of action is typically 12 weeks (for genotype 1 and 3 without cirrhosis) and up to 24 weeks for certain patient populations.
Alcohol consumption is not recommended during treatment.
The most common side effects are headache and fatigue.
Would you like to try Daclatasvir without a prescription?

Basic Daclatasvir Information

• INN (International Nonproprietary Name): Daclatasvir
• Brand names available in USA: Daklinza®
• ATC Code: J05AP07
• Forms and dosages: Tablets – 30 mg, 60 mg
• Manufacturers in USA: Bristol‑Myers Squibb (originator); generics may be available in some countries
• Registration status in USA: Approved by FDA (2015)
• OTC / Rx classification: Prescription only (Rx)

Mechanism and Pharmacology

Daclatasvir is a direct‑acting antiviral agent that inhibits the hepatitis C virus NS5A protein, which is essential for viral RNA replication and assembly. By binding to NS5A, daclatasvir disrupts the formation of the viral replication complex, leading to a rapid decline in HCV RNA levels. It has activity against HCV genotypes 1‑4, with highest potency against genotypes 1a, 1b, and 3a. Daclatasvir is primarily metabolized by CYP3A4 and is a substrate of P‑glycoprotein (P‑gp).

Indications and Usage

Daclatasvir is indicated for the treatment of chronic hepatitis C virus infection in adults, in combination with sofosbuvir, with or without ribavirin, for specific genotypes (1, 3). It is used for patients with or without cirrhosis (compensated) and for those who are treatment‑naïve or treatment‑experienced, including prior treatment with peginterferon/ribavirin. Daclatasvir is also indicated for patients with HCV/HIV‑1 coinfection. The regimen achieves cure (SVR12) in over 95% of patients for genotype 1 and 85‑95% for genotype 3.

Critical Warnings and Limitations

High‑Risk Groups
Elderly: No dose adjustment required based solely on age; use with caution in patients with significant renal impairment.
Pregnancy: Insufficient data in pregnant women; use only if potential benefit justifies potential risk. When used with ribavirin, ribavirin is teratogenic – effective contraception required for both male and female patients during and for 6 months after therapy.
Breastfeeding: Unknown whether daclatasvir passes into breast milk; advise caution.

Activity Interactions
Driving: May cause fatigue or dizziness – use caution when operating vehicles or machinery.
Alcohol: Avoid alcohol consumption as it may worsen liver damage and reduce treatment adherence.

Dosage Guide

Standard Regimens
Recommended dosage: 60 mg taken orally once daily, with or without food, in combination with sofosbuvir (400 mg once daily). Treatment duration depends on genotype and cirrhosis status:
- Genotype 1, without cirrhosis: 12 weeks.
- Genotype 1, with compensated cirrhosis: 12 weeks.
- Genotype 3, without cirrhosis: 12 weeks.
- Genotype 3, with compensated cirrhosis: 12 weeks + ribavirin (weight‑based) OR 24 weeks (without ribavirin).
- Post‑liver transplant (any genotype): 12 weeks + ribavirin.
- For patients with decompensated cirrhosis (Child‑Pugh B/C): 12 weeks + ribavirin.

Special Populations
Renal impairment: No dose adjustment for mild, moderate, or severe renal impairment (including ESRD on hemodialysis). However, caution advised as safety data are limited.
Hepatic impairment: No dose adjustment for mild, moderate, or severe (Child‑Pugh A, B, C) hepatic impairment.
Pediatric: Safety and efficacy in children under 18 years have not been established.

Side Effects and Contraindications

Common side effects:
- Headache
- Fatigue
- Nausea
- Diarrhea
- Insomnia
- Abdominal pain

Serious side effects requiring medical attention:
- Symptomatic bradycardia when coadministered with amiodarone (especially with sofosbuvir)
- Hepatitis B reactivation in patients coinfected with HBV and HCV (screen all patients for HBV)
- Severe allergic reactions (rash, angioedema)
- Elevated liver enzymes (rare)

Absolute contraindications:
- Hypersensitivity to daclatasvir or any excipient
- Coadministration with strong inducers of CYP3A4 (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) – contraindicated due to reduced daclatasvir levels and potential loss of efficacy.
- For regimens containing ribavirin: pregnancy, severe renal impairment (eGFR

Drug Interactions

Significant interactions include:
- Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John’s wort): Significantly decrease daclatasvir levels – contraindicated.
- Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir): Increase daclatasvir levels; dose reduction of daclatasvir to 30 mg once daily may be required.
- Moderate CYP3A4 inducers (efavirenz, etravirine, modafinil): Increase daclatasvir dose to 90 mg once daily.
- Antacids and proton pump inhibitors (PPIs): Daclatasvir solubility is pH‑dependent; separate administration by at least 4 hours or take with food.
- Amiodarone: Risk of severe bradycardia when used with sofosbuvir – avoid or monitor closely.
- Statins (rosuvastatin, atorvastatin): Daclatasvir may increase statin levels; monitor for myopathy.

Practical Guidelines

Administration
Take Daclatasvir once daily at the same time each day, with or without food. Swallow tablet whole; do not crush or chew. If a dose is missed, take it as soon as remembered unless it is within 8 hours of the next dose; if so, skip the missed dose. Do not double dose. Complete the full prescribed course to achieve cure.

Monitoring
Regular blood tests required before and during treatment:
- HCV RNA viral load (baseline, week 4, end of treatment, and 12 weeks post‑treatment)
- Liver function tests (ALT, AST, bilirubin)
- Renal function (creatinine, eGFR)
- HBV screening (HBsAg, anti‑HBc) to detect risk of reactivation
- Pregnancy test for women of childbearing potential (if ribavirin is used)

Storage
Store at room temperature (20‑25°C / 68‑77°F), excursions permitted to 15‑30°C (59‑86°F). Protect from moisture and heat. Keep tablets in original container, tightly closed.

Alternative Medications

• Epclusa (sofosbuvir/velpatasvir): Pan‑genotypic, 12‑week treatment, no need for ribavirin in most patients.
• Mavyret (glecaprevir/pibrentasvir): Pan‑genotypic, 8‑week treatment for non‑cirrhotic patients.
• Harvoni (ledipasvir/sofosbuvir): For genotypes 1, 4, 5, 6; 8‑12 weeks.
• Vosevi (sofosbuvir/velpatasvir/voxilaprevir): For retreatment after prior DAA failure.
• Zepatier (elbasvir/grazoprevir): For genotypes 1 and 4; requires baseline resistance testing.

Clinical Effectiveness

In pivotal clinical trials (ALLY‑1, ALLY‑2, ALLY‑3), daclatasvir plus sofosbuvir achieved SVR12 rates of 95‑99% for genotype 1, 92‑97% for genotype 3, and 89‑94% for patients with decompensated cirrhosis (when ribavirin was added). The regimen is well‑tolerated with low rates of serious adverse events. Daclatasvir has a high barrier to resistance, though baseline NS5A resistance‑associated substitutions (RASs) may reduce efficacy, particularly in genotype 1a and 3. Resistance testing is recommended for genotype 3 and for treatment‑experienced patients.

Important: Daclatasvir requires medical supervision and should only be used under prescription. Do not stop treatment without consulting your doctor. Complete the full course as prescribed to achieve cure. Regular monitoring for HBV reactivation and drug interactions is essential. If you experience signs of bradycardia (dizziness, fainting, chest pain) while on amiodarone, seek immediate medical attention.

How to buy Generic Daclatasvir no prescription U.S. Online Pharmacy